Santhera Pharmaceutical Holding Ltd

Santhera Pharmaceuticals

Santhera is a Swiss specialty pharmaceutical company focusing on the discovery, development and marketing of small molecule products for the treatment of orphan neuromuscular diseases, an area of high unmet medical needs.

Products & Pipeline

Santhera has three compounds in development for seven orphan neuromuscular indications. Catena® is Santhera's first product, approved under conditions in Canada for symptomatic treatment of Friedreich's Ataxia.

Clinical Development Programs

Santhera is currently recruiting patients for clinical studies in Leber's Hereditary Optic Neuropathy; in MELAS and in Primary Progressive Multiple Sclerosis

Latest News

June 30, 2009
Santhera's FJORD Phase IIb Study Demonstrates Efficacy of JP-1730/Fipamezole for the Treatment of Dyskinesia in Parkinson's Disease
---
June 26, 2009
Santhera Enters Agreement with Columbia University to Investigate Additional Potential of Catena® in MELAS